

AD _____

Award Number: W81XWH-04-1-0166

TITLE: Immune Cells, If Rendered Insensitive to Transforming Growth Factor-Beta, Can Cure Prostate Cancer

PRINCIPAL INVESTIGATOR: Chung Lee, Ph.D.

CONTRACTING ORGANIZATION: Northwestern University
Evanston, IL 60208-0110

REPORT DATE: February 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20060525043

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-02-2006		2. REPORT TYPE Annual		3. DATES COVERED 2 Jan 2005 – 1 Jan 2006	
4. TITLE AND SUBTITLE Immune Cells, If Rendered Insensitive to Transforming Growth Factor-Beta, Can Cure Prostate Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0166	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Chung Lee, Ph.D.				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Northwestern University Evanston, IL 60208-0110				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The objective of the current proposal is to perform immunotherapy to eradicate prostate cancer and at the same time to avoid the development of autoimmune disease. The proposal contains two tasks. The first task is a combination of TGF-beta insensitive tumor-reactive T cell adoptive therapy for the treatment of mouse prostate cancer. The second task is an inducible TGF-beta based gene therapy. At the time of this report, we have completed Task 1 and a paper has been published (Cancer Research 65:1761-1769, 2005; Prostate 66:235-247, 2005). Currently, we have modified approaches for studies described in Task 2. Instead of using the tetracycline-inducible system, we have adapted a herpes simplex thymidine kinase/ganciclovir system, which is working successfully and is in the final phase of completing the task.					
15. SUBJECT TERMS Prostate Cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	30	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	6
References.....	7
Appendices.....	8

INTRODUCTION :

During the funding period, we have completed studies described in Task 1. Currently, studies described in Task 2 are underway. Briefly, the progress can be summarized in two papers that have been published in *Cancer Research* 65:1761-1769 and in *Prostate* 66:235-247. In these papers, we reported the successful eradication of mouse prostate cancer by adoptive transfer of tumor-reactive TGF-beta insensitive CD8+ T cells in tumor bearing mice. In Task 2, we have encountered some technical problem in conducting the tetracycline inducible (Tet-on) system in vivo. We have now changed to using the herpes simplex virus thymidine kinase (*HSV-tk*)/ganciclovir (GCV) inducible system, which has been working successfully for us. The project is in its final in vivo phase.

BODY :

Task 1. To perform a tumor-reactive TGF-beta insensitive CD8+ T cells in an adoptive therapy of tumor bearing mice (see publication by Zhang et al, 2005a,b)

- * We have successfully isolated tumor-reactive CD8+ T cells from donor mice by vaccinating these mice with irradiated TRAMP-C2 mouse prostate cancer cells. The spleen of these vaccinated mice was isolated and CD8+ T cells were isolated.

- * The isolated CD8+ T cells were expanded ex vivo in the presence of lysates of TRAMP-C2 cells, irradiated spleen cells (as the antigen presenting cells), IL-2, and antiCD3 antibody.

- * We have inserted a dominant negative TGF- β type II receptor (dnT β RII) expression vector MSC retrovirus gene into the above mentioned tumor reactive CD8+ T cells. Under a separate start site, a green fluorescent protein expressed vector was inserted into the same retrovirus gene.

- * We have successfully transferred the tumor-reactive TGF-beta insensitive CD8+ T cells to the tumor-bearing male C57BL/6 mice.

- * Tumor cells were injected into above recipient mice at 21 days prior to adoptive transfer of CD8+ T cells. At 40 days after the adoptive transfer, animals were sacrificed for inspection of the status of metastasis of TRAMP-C2 mouse prostate cancer cells into the lung.

- * In mice received naïve CD8+ T cells, the majority of the tumors were not rejected. In animals received tumor-reactive control CD8+ T cells, there was a partial tumor rejection. However, in animals received adoptive transfer of tumor-reactive TGF-beta insensitive CD8+ T cells, most of the tumors were rejected with no apparent toxicity.


Task 2: During the course of performing studies described in Task 2, we have encountered technical difficulty in that we were unable to introduce the Tet-on system in our proposed in vivo study. Therefore, we have sought alternative approaches and we have decided to use another inducible system for Task 2 studies as described below.

In a mammalian cell system, herpes simplex virus thymidine kinase (*HSV-tk*) can phosphorylate certain nucleotide analogues such as ganciclovir (GCV) that are not metabolized by conventional cellular enzymes. Phosphorylated nucleoside analogues such as GCV triphosphate are potent toxic metabolites for cells. Nevertheless, neither GCV nor HSV-tk alone is harmful to cells. Hence, a conditional cell-depleting effect can be achieved by expressing *HSV-tk*. Such a HSV-tk/GCV mediated conditional cell-depleting system has been used for the depletion of specially selected cell types by many investigators for more than seventeen years (Minasi et al, 1993; Salomen et al, 1994; Tian et al, 2003; Rettig et al, 2004). In the present study, we proposed to use this system to conditionally deplete the TGF- β insensitive bone marrow cells.

In collaboration with Dr. Isaac Kim, currently at the Cancer Institute of New Jersey, we have modified the original retroviral vector with T β RIIDN (Shah et al, 2002a,b) to connect the HSV-tk as the intracellular domain of the T β RIIDN molecule. As such, the viral vector is still function as the dominant negative T β RII. When this viral vector is infected into the target cell,


the cell will not only be insensitive to TGF- β but will also express thymidine kinase as depicted below.

T β RIIDN-tk Construct:






The control vector to the above construct is designed by excising the extracellular domain of the T β RIIDN molecule but retaining the transmembrane domain so that the HSV-tk is still anchored as part of the intracellular domain of the truncated T β RIIDN. When this control vector is infected into the target cell, the cell is unable to bind TGF- β but will express thymidine kinase as indicated below.

TRANS-tk Construct (Control vector):



Results of our preliminary study using NIH 3T3 cells as the target have demonstrated efficacy of these constructs. The infection rate in NIH-3T3 cells was over 90% and the sensitivity to TGF- β in these cells is depicted below. When these cells were treated with GCV (10 μ g/ml), they rapidly lose the viability and the rate of 3 H-thymidine incorporation. They also have lost the sensitivity to TGF- β , as indicated by a lack of PAI-I luciferase activity when they were treated with TGF- β 1.



In this experiment, we will infect bone marrow cells with the above two types of virus carrying either the T β RIIDN-tk vector or the TRANS-tk vector. Next, we will perform the in vitro sensitivity toward TGF- β . The TGF- β sensitivity test will include 3 H-thymidine incorporation assay, Smad-2 phosphorylation assay, and PAI-I promoter-reporter assay with and without the presence of TGF- β 1 (5 ng/ml), as described earlier (Shah et al, 2002a; Zhang et al, 2005a). When in vitro tests are completed, we will conduct the in vivo study, the final phase of this task.

KEY RESEARCH ACCOMPLISHMENTS:

- We have developed an immunotherapy approach in which we perform adoptive transfer of tumor-reactive TGF-beta insensitive CD8⁺ T cells into tumor bearing mice. These animals were able to reject established mouse prostate tumors metastasized into the lung.

REPORTABLE OUTCOMES:

As a result of this research funded by the Department of Defense, we have published two papers (see appendix).

CONCLUSIONS:

Immunotherapy using adoptive transfer of immune cells is a promising approach for treating cancer patients. The presence of tumor infiltrating lymphocytes (TIL) in the tumor parenchyma has been recognized for three decades¹. TIL were isolated from surgical specimens, clonally expanded by ex vivo culture, and adoptively transferred to the cancer patients with variable results^{2,3}. Recently, Yee and coworkers selected antigen specific CD8⁺ T cells for ex vivo expansion and transferred these cells into patients. These CD8⁺ T cells did not persist, requiring repeated transfer of CD8⁺ T cells in order to elicit responses from the patients⁴. Rosenberg and colleagues treated autologous TIL cells with IL-2 for ex vivo expansion and then transferred them to patients. Again, in order for these cells to "engraft", lymphodepletion was necessary⁵. These results, although impressive, fall short of our expectation, i.e., total elimination of tumor cells in most patients.

One of the reasons for the failure of TIL in treating cancer is perhaps the fact that the functional role of TIL in cancer has been a subject of controversy⁶. Initially, it appeared that the presence of TIL in the tumor could correlate to prognosis⁷. Subsequent studies showed that TIL were functionally impaired⁸⁻¹⁰. This impairment of TIL has been attributed to effects exerted by the tumor microenvironment¹¹. When developing an immune-based strategy for cancer therapy, in addition to immune stimulation, the issue of overcoming tumor-derived immune suppression must be taken into consideration¹². There are 6 potential mechanisms of tumor immune escape: loss of tumor antigen expression; variations in tumor antigen; defects in the transporter associated with antigen presentation; defects in expression of the MHC heavy chain; expression of immunoprotective molecules and release of molecules by tumor cells that disrupt T-cell signaling or induce T-cell death; and upregulation of the expression of immunoprotective molecules (PI9, FLIP and the IAP family) that counteract the effects of FASL, granzyme B, CXCL12, FLIP, FLICE, IAP, IL-10, PI9, RCAS1 and TGF- β . Among these molecules, TGF- β is an important immunosuppressant¹³.

TGF- β has been recognized as a potent immunosuppressive factor¹⁴⁻¹⁸. The high levels of TGF- β produced by cancer cells have a negative effect on surrounding cells, including the host immune cells and have been implicated to play a role in tumor escape from immune surveillance^{19,20}. Besides the tumor, the immune system, in response to the presence of tumor, is also able to produce a significant amount of TGF- β to down regulate immune surveillance²¹.

In light of the above discussion, TGF- β appears to be an attractive target for anti-cancer therapy. Attempts to take advantage of the properties of TGF- β for the treatment of cancer have been reported. Gorelik and Flavell first described the immune-mediated eradication of tumors through the blockade of TGF- β signaling in T cells¹⁷. These investigators used transgenic mice with TGF- β null expression targeted specifically to T cells. Subsequently, our study using transplant of TGF- β -insensitive bone marrow cells also demonstrated a total rejection of metastatic tumor cells^{22,23}. However, in both studies, due to the non-specific nature of the immune cells, autoimmune disease eventually developed in the hosts. Results of our recent study have shown that adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells were able to eradicate established lung metastasis of mouse prostate cancer cells, TRAMP-C2²⁴. In the present study, we continue to employ this novel gene therapy approach to investigate the ability these CD8⁺ T cells to infiltration into the tumor parenchyma. Here, we report that these

CD8⁺ T cells show a distinct ability to infiltrate into established tumors, secrete relevant cytokines, and induce apoptosis of tumor cells.

References:

1. Ioachim, H.L. The stroma reaction of tumor: An expression of immune surveillance. *J Cell Biochem. Suppl.* **57**, 465-475 (1979).
2. Economou, J.S. *et al.* In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. *J. Clin. Invest.* **97**, 515-521 (1996).
3. Figlin, R.A. *et al.* Multicenter, randomized, phase III trial of CD8⁺ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. *J. Clin. Oncol.* **17**, 2521-2529 (1999).
4. Yee, C. *et al.* Adoptive T cell therapy using antigen-specific CD8⁺ T cells clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. *Proc. Natl. Acad. Sci. USA.* **99**, 16168-16173 (2002).
5. Rosenberg, S.A. & Dudley, M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. *Proc. Natl. Acad. Sci. USA* **101**, 14639-14645 (2004).
6. Miescher, S., Whiteside, T.L., Moretta, L. & Von, F.V. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. *J Immunol.* **138**, 4004-4011 (1987).
7. Svennevig, J.L., Lunde, O.C., Holter, J. & Bjorgsvik, D. Lymphoid infiltration and prognosis in colorectal carcinoma. *Br J Cancer* **49**, 375-377 (1984).
8. Whiteside, T.L. Tumor infiltrating lymphocytes as antitumor effector cells. *Biotherapy.* **5**, 47-61 (1992).
9. Meischer, S. *et al.* Proliferative and cytolytic potentials of purified tumor infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T cell receptor expression. *Int J Cancer* **42**, 659-666 (1998).
10. Reichert, T.E. *et al.* Signaling abnormality, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. *Clin Cancer Res.* **8**, 3133-3145 (2002).
11. Rabinowich, H. *et al.* Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. *Int J Cancer* **68**, 276-284 (1996).
12. Dudley, M.E. & Rosenberg, S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. *Nat. Rev. Cancer* **3**, 666-675 (2003).
13. Yee, C. & Greenberg, P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. *Nature Rev. Cancer* **2**, 409-419 (2002).
14. Wojtowicz, P.S. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy. *J Immunother.* **20**, 165-177 (1997).
15. Letterio, J.J. & Roberts, A.B. Regulation of immune responses by TGF- β . *Ann Rev Immunol.* **13**, 51-69 (1998).
16. Fortunel, N.O., Hatzfeld, A. & Hatzfeld, J. Transforming growth factor- β : pleiotropic role in the regulation of hematopoiesis. *Blood* **96**, 2022-2036 (2000).
17. Gorelik, L. & Flavell, R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor- β signaling in T cells. *Nat Med.* **7**, 1118-1122 (2001).
18. Kao, J.Y. *et al.* Tumor-derived TGF- β reduces the efficacy of dendritic cell/tumor fusion vaccine. *J Immunol.* **170**, 3806-3811 (2003).
19. Won, J. *et al.* Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. *Cancer Res.* **59**, 1273-1277 (1999).

20. de Visser, K.E. & Kast, MW. Effects of TGF- β on the immune system: implications for cancer immunotherapy. *Leukimia*. **13**, 188-1199 (1999).
21. Terabe, M. et al. Transforming growth factor- β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. *J Exp Med*. **198**, 1741-1752 (2003).
22. Shah, A.H. et al. Reconstitution of lethally irradiated mice with TGF-b insensitive bone marrow leads to myeloid expansion and inflammatory disease. *J. Immunol*. **169**, 3485-3491 (2002).
23. Shah, A.H. et al. Suppression of tumor metastasis by blockade of TGF-b signaling in bone marrow cells through a retroviral mediated gene therapy in mice. *Cancer Res*. **62**, 7135-7138 (2002).
24. Zhang, Q. et al. Adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells: Eradication of autologous mouse prostate cancer. *Cancer Res*. **65**, (in press March 2005).

APPENDICES:

- Zhang Q, Yang X, Pins M, Liu V, Jovanovic B, Kuzel T, Kim S-J, Van Parijs L, Greenberg NM, Guo Y, Lee C. (2005) Adoptive transfer of tumor reactive TGF- β insensitive CD8⁺ T cells: Eradication of autologous mouse prostate cancer. *Cancer Research* 65:1761-1769.
- Zhang Q, Jang TL, Yang X, Pins M, Jovanovic B, Kuzel T, Kim S-J, Van Parijs L, Smith N, Greenberg NM, Guo Y, Lee C. (2005) Infiltration of tumors specific transforming growth factor-beta insensitive CD8⁺ T cells into tumor parenchyma is associated with apoptosis in tumor cells *Prostate* 66:235-247.

Adoptive Transfer of Tumor-Reactive Transforming Growth Factor- β -Insensitive CD8⁺ T Cells: Eradication of Autologous Mouse Prostate Cancer

Qiang Zhang,¹ Ximing Yang,² Michael Pins,² Borko Javonovic,³ Timothy Kuzel,⁴ Seong-Jin Kim,⁵ Luk Van Parijs,⁶ Norman M. Greenberg,⁷ Victoria Liu,¹ Yinglu Guo,⁸ and Chung Lee¹

Departments of ¹Urology, ²Pathology, ³Preventive Medicine, and ⁴Medicine, Northwestern University's Feinberg School of Medicine, Chicago, Illinois; ⁵Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland; ⁶Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts; ⁷Fred Hutchinson Cancer Research Center, Seattle, Washington; and ⁸Institute of Urology, Peking University, Beijing, China

Abstract

Transforming growth factor (TGF)- β is a potent immunosuppressant. Overproduction of TGF- β by tumor cells may lead to tumor evasion from the host immune surveillance and tumor progression. The present study was conducted to develop a treatment strategy through adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells. The mouse TRAMP-C2 prostate cancer cells produced large amounts of TGF- β 1 and were used as an experimental model. C57BL/6 mice were primed with irradiated TRAMP-C2 cells. CD8⁺ T cells were isolated from the spleen of primed animals, were expanded *ex vivo*, and were rendered TGF- β insensitive by infecting with a retrovirus containing dominant-negative TGF- β type II receptor. Results of *in vitro* cytotoxic assay revealed that these CD8⁺ T cells showed a specific and robust tumor-killing activity against TRAMP-C2 cells but were ineffective against an irrelevant tumor line, B16-F10. To determine the *in vivo* antitumor activity, recipient mice were challenged with a single injection of TRAMP-C2 cells for a period up to 21 days before adoptive transfer of CD8⁺ T cells was done. Pulmonary metastasis was either eliminated or significantly reduced in the group receiving adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells. Results of immunofluorescent studies showed that only tumor-reactive TGF- β -insensitive CD8⁺ T cells were able to infiltrate into the tumor and mediate apoptosis in tumor cells. Furthermore, transferred tumor-reactive TGF- β -insensitive CD8⁺ T cells were able to persist in tumor-bearing hosts but declined in tumor-free animals. These results suggest that adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells may warrant consideration for cancer therapy. (Cancer Res 2005; 65(5): 1761-9)

Introduction

Adoptive therapy using antigen-specific immune cells from patients has become an attractive approach for tumor immunotherapy (1). The procedure has been effective in cases of low tumor burden. Increased knowledge of immunoregulation and immune function of effector cells has led to the development of specific cell therapy with the objective of targeting tumor cells for destruction.

The ultimate effector cell that facilitates tumor rejection in preclinical animal models is CD8⁺ T cells (1).

Historically, adoptive transfer of lymphokine-activated killer cells was first attempted, in which *ex vivo* culture of autologous lymphocytes with interleukin 2 (IL-2) to increase the number of activated effector cells. However, a clinical benefit was not shown by this approach (2). Subsequently, tumor-infiltrating lymphocytes were isolated from surgical specimens, clonally expanded by *ex vivo* culture with IL-2, and adoptively transferred to the patient (3). Although the initial results were promising, results of a phase III randomized trial using CD8⁺ tumor-infiltrating lymphocytes in combination with IL-2 failed to show an improved response in patients with metastatic renal cell carcinoma (4). Two recent studies represent the state-of-the-art strategies in adoptive therapy for cancer. In the first study (5), authors selected antigen-specific CD8⁺ T cells for *ex vivo* expansion and transfer into patients. Responses were remarkable but these CD8⁺ T cells did not persist, requiring repeated transfer of CD8⁺ T cells to elicit responses from the patients. In the second study (6), authors treated autologous tumor-infiltrating lymphocyte cells with IL-2 for *ex vivo* expansion and then transferred to patients following lymphodepletion. Although long-term engraftment was achieved, only 4 of 35 patients showed complete response. These results, although impressive, fall short of our expectation (i.e., total elimination of tumor cells in most patients).

In considering tumor immunotherapy, the issue of tumor-derived immune suppression must be taken into consideration (1). It seems that despite the ability to generate immune cells reactive against cancer antigens, tumor escape mechanisms can overpower these immune reactions with an eventual tumor progression (7). Tumor cells have acquired many mechanisms to evade the host immune surveillance (8, 9). One of such possibilities has been the down-regulation of tumor antigen processing (10). Tumor-specific CD4⁺CD25⁺ T regulatory cells can also inhibit CD8⁺ T-cell function (11). Tumor-derived immunosuppressive cytokines, including vascular endothelial growth factor, IL-10, and transforming growth factor (TGF)- β (9, 12-14), also contribute to tumor evasion of the host immune surveillance. In the present study, we propose to focus on TGF- β -mediated evasion of immune surveillance.

Tumor cells secrete large amounts of TGF- β . High levels of TGF- β produced by cancer cells have a negative impact on surrounding cells, including the host immune cells (15). TGF- β is a potent tumor-induced immunosuppressant (8, 12, 16-20). Therefore, TGF- β seems to be an attractive target for anticancer therapy. The first piece of work describing immune-mediated eradication of tumors through the blockade of TGF- β signaling in T cells was reported by Gorelik and Flavell (17). These authors used transgenic mice with

Requests for reprints: Chung Lee, Northwestern University's Feinberg School of Medicine, 303 East Chicago Avenue, Tarry 16-733, Chicago, IL 60611. Phone: 312-908-2004; Fax: 312-908-7572; E-mail: c-lee7@northwestern.edu.
©2005 American Association for Cancer Research.




Figure 1. A, secretion of TGF- β 1 levels by different cell lines. TGF- β 1 present in the conditioned media over a period of 48 hours was determined by ELISA (see Materials and Methods) and was expressed as pg per 10^5 cells per 48 hours. TRAMP-C2, mouse prostate cancer cell line; B16, mouse melanoma cell line; Renca, mouse renal cell carcinoma cell line; LNCaP and PC3, human prostate cancer cell lines; TSU-Pr1, human bladder cancer cell line, RWPE-1, immortalized human normal prostate epithelium cell line. Bars, SD. B, expression of TGF- β type I (T β RI) and type II receptors (T β RII) in normal mouse splenic CD8⁺ T cells. Analysis was done by double-labeled immunofluorescent FACS (CD8⁺-FITC, TGF- β receptors-phycoerythrin; see Materials and Methods).

TGF- β null expression targeted specifically to T cells. Subsequently, our study using transplant of TGF- β -insensitive bone marrow cells also showed a total rejection of metastatic tumor cells (19, 20). However, in both studies, due to the nonspecific nature of the immune cells, autoimmune disease eventually developed in the hosts.

In the present study, we attempted to combine the above two advanced technologies by employing adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells into tumor-bearing mice. Here, we report that these CD8⁺ T cells showed a robust antitumor activity with little or no apparent toxicity.

Materials and Methods

Mice and Cells. Male C57BL/6 mice ages 6 to 8 weeks were purchased from The Jackson Laboratory (Bar Harbor, ME) and were maintained in pathogen-free facilities at the Center for Comparative Medicine at Northwestern University's Feinberg School of Medicine in accordance with established guidelines of the Animal Care and Use Committee of Northwestern University. TRAMP-C2 cells obtained from Dr. N. Greenberg (Fred Hutchinson Cancer Research Center, Seattle, WA) were maintained in RPMI 1640 (Life Technologies, Rockville, MD) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies), 100 units/mL penicillin, and 100 μ g/mL streptomycin.

Generation of Tumor-Reactive CD8⁺ T Cells. Mice were primed with irradiated TRAMP-C2 cells (5×10^6 per mice at 20,000 Ci) by s.c. injection every 10 days for a total of three inoculations. Two weeks following the last vaccination, splenic CD8⁺ T cells were isolated by using murine T cell CD8⁺ subset column kit (R&D Systems, Minneapolis, MN) and were

expanded (10^5 /mL) in the presence of TRAMP-C2 lysates (1×10^6) and irradiated autologous splenocytes (1×10^6 /mL at 3,000 Ci) in medium containing RPMI 1640 with 10% fetal bovine serum, IL-2 (50 units/mL), anti-CD3⁺ monoclonal antibody (30 ng/mL, R&D Systems), HEPE (25 mmol/L), L-glutamine (4 mmol/L), and 2-ME (25 mmol/L). Media were changed every 3 days.

Infection with Retrovirus Containing Dominant Negative TGF- β Type II Receptor or Green Fluorescent Protein. CD8⁺ T cells were cultured for at least 10 weeks before they were infected with the murine stem cell virus retrovirus containing the dominant-negative TGF- β type II receptor (T β RIIDN) and green fluorescent protein (GFP; Fig. 2A; refs. 19, 20). The infection efficiency was 93.9% for the T β RIIDN vector and 92.8% for the GFP control vector (Fig. 2B). There were three types of CD8⁺ T cells. The first type was tumor-reactive TGF- β -insensitive CD8⁺ T cells (tumor-reactive CD8⁺ T cells infected with the virus containing T β RIIDN). The second type was tumor-reactive CD8⁺ T cells infected with the virus containing the GFP control vector. The third type was naive CD8⁺ T cells, which were freshly isolated from the spleen of naive donor animals without any treatment.

In vitro CTL Assay. The above three types of CD8⁺ T cells were subjected to a standard ⁵¹Cr release assay (20). TRAMP-C2 cells were used as targets. An irrelevant cancer cell line, mouse melanoma cell line, B16-F10, was used as a nonspecific control. Target cells were labeled with 0.1 mCi of ⁵¹Cr per 10^6 cells for 4 hours at 37°C, followed by 5 washes in HS-4 media and were seeded in 96-well U-bottomed plates (5,000 cells/well). CD8⁺ T cells were added at different effector/target ratios (1:1 to 100:1) for 5 hours. The supernatants were harvested using the Skatron filters (Skatron Instruments, Sterling, VA) and the released radioactivity was measured using a gamma counter (LKB Wallac, Turku, Finland). The percent of specific lysis was determined as $100 \times [(\text{Experimental } ^{51}\text{Cr Release} - \text{Spontaneous } ^{51}\text{Cr Release}) / (\text{Maximum } ^{51}\text{Cr Release} - \text{Spontaneous } ^{51}\text{Cr Release})]$.

Release)). The maximum release was determined by adding 2% SDS to target cells.

In vivo Antitumor Assay. Mice received a single injection of 5×10^5 TRAMP-C2 cells via the tail vein. Adoptive transfer of CD8⁺ T cells (2×10^6) was done on either day 3, 7, or 21 following tumor cell injection. Mice were maintained on antibiotics (sulfamethoxazole-trimethoprim) for a minimum of 2 weeks to prevent opportunistic infection after the injection. Forty days after the adoptive transfer, all animals were sacrificed. Some animals were sacrificed sooner than 40 days due to poor health conditions. Serum levels of IFN- γ and IL-2 were determined by ELISA. Splenic CD8⁺ T cells were

isolated, and the percentage of GFP-positive CD8⁺ T cells in each spleen was calculated following analysis by flow cytometry.

Histologic Procedures. For each animal, upon euthanasia, the lung was excised, fixed in formalin, embedded in paraffin, and serially sectioned at 4- μ m thickness until the block was exhausted. Routine H&E staining was done at an interval of every 10 sections. The unstained paraffin sections were used for studies described below.

Nuclear Staining, Apoptosis Assay, and CD8⁺ Staining. Tissue sections were subjected to apoptosis assay by using the TUNEL apoptosis kit (Upstate, Lake Placid, NY) and were labeled with Avidin-FITC




Figure 2. Structure, function, and expression of dominant-negative T β RIIDN. **A**, schematic diagram of the murine stem cell virus (MSCV) retroviral construct. A truncated sequence of the human T β RIIDN, lacking the intracellular kinase signaling domain, was cloned into the pMig-internal ribosomal entry sequence (IRES)-GFP vector. The control construct (not shown) contained the GFP vector only and without the T β RIIDN sequence (325-902 bp). **B**, fluorescent-activated cell sorting analysis of murine CD8⁺ T cells transfected with the T β RIIDN vector (93.9%) and the GFP control vector (92.8%). The high efficiency of infection of the viral transgene into CD8⁺ T cells allowed us to perform adoptive transfer directly without the need of sorting. **C-E**, series of functional analysis done following the treatment of CD8⁺ T cells with 10 ng/mL TGF- β 1. **C**, phosphorylation of Smad-2 observed in naive CD8⁺ T cells and in tumor-reactive CD8⁺ T cells infected with the GFP control vector but not observed in tumor-reactive CD8⁺ T cells infected with the T β RIIDN vector. Blots were stripped and reprobed with anti-Smad-2 and anti-GAPDH antibodies as loading controls. **D**, luciferase activity in CD8⁺ T cells transfected by TGF- β signal-specific plasminogen activator inhibitor-1 promoter-luciferase reporter construct and treated with TGF- β 1. **E**, [³H]-thymidine incorporation into CD8⁺ T cells before and after the treatment with TGF- β 1. Bars, SD.

(green, 50 μ L). The same slides were treated with blocking buffer and probed for CD8 with rat monoclonal antibody, which was labeled with APC (red; 2 μ g/mL, Santa Cruz Biotechnology, Santa Cruz, CA). Finally, the same slides were stained for cell nuclei with VECTASHIELD mounting media (blue; Vector Laboratories, Burlingame, CA). They were viewed with Nikon TE2000-U fluorescent microscopy (Nikon Co., Tokyo, Japan). Images were digitized by Photoshop 7.0 software.

Expression of TGF- β Receptors in CD8⁺ T Cells. Normal CD8⁺ T cells, isolated from freshly harvested spleens, were subjected to fixation and permeabilization in preparation for immunofluorescent staining and flow cytometry analysis. Cells were stained with phycoerythrin-conjugated monoclonal antibody against TGF- β type I receptor (1:100 dilution; Santa Cruz Biotechnology), and TGF- β type II receptor (1:50 dilution, Santa Cruz Biotechnology). They were then stained with FITC-conjugated monoclonal antibody against CD8 (Santa Cruz Biotechnology). These cells were subjected to dual analysis for phycoerythrin and FITC by flow cytometry.

Western Blot Analysis for SMAD-2 Phosphorylation. CD8⁺ T cells were treated with or without 10 ng/mL of TGF- β 1 for 16 hours (19). Cell

lysates were prepared by adding radioimmunoprecipitation assay buffer (50 mmol/L Tris-HCl, 1% NP40, 0.25% Na-deoxycholate, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L Na₃VO₄, and 1 mmol/L NaF) to cell pellets. Approximately 30 μ g of total protein extract were loaded onto 10%




Figure 3. *In vitro* CTL assays. CTL was done using the conventional ⁵¹Cr release assay (see Materials and Methods). Naive CD8⁺ T cells, GFP, and T β RIIDN transfected CD8⁺ T cells were cocultured with ⁵¹Cr-labeled targets at the specified E/T ratios. **A**, TRAMP-C2 mouse prostate cancer cells were used as the targets; **B**, B16-F10 mouse melanoma cells were used as targets. Point, average observations obtained from eight wells; bars, SD.




Figure 4. Status of pulmonary metastasis of TRAMP-C2 tumors in mice received adoptive transfer of three types of CD8⁺ T cells. Recipient mice received a single injection of TRAMP-C2 cells (5×10^5). At 3, 7, or 21 days following the initial tumor challenge, adoptive transfer of CD8⁺ T cells was done. Animals were sacrificed at 40 days following the adoptive transfer or sooner due to poor health conditions. **A**, representative gross feature of lung tissues from tumor-bearing mice at 40 days following the administration of adoptive transfer. **B**, status of pulmonary metastasis of mouse prostate cancer. The presence of gross and microscopic pulmonary metastasis in each treatment group was tabulated and expressed as the number of animals with pulmonary metastasis (% total animals in each group) as well as the average number of metastatic sites per animal. Results of the statistical analysis, using the χ^2 test, indicated that values in the T β RIIDN group are significantly different from those of other two groups ($P < 0.001$). Also, values in the GFP group are significantly different from those of the naive group ($P < 0.001$). **C**, Kaplan-Meier survival curve of tumor-bearing mice received adoptive transfer of naive CD8⁺ T cells (dotted line with solid circles), GFP control vector (solid line with solid circles), and T β RIIDN-transfected CD8⁺ T cells (dotted line with open circles). $P < 0.05$ according to the log-rank test for the T β RIIDN group versus the naive or GFP group.




Figure 5. Representative histologic features (H&E staining) of metastatic tumor nodules in the lungs from animals received adoptive transfer of naive CD8⁺ T cells (A and D), GFP-infected tumor reactive CD8⁺ T cells (B and E), and T β RIIDN-infected tumor reactive CD8⁺ T cells (C and F) mice 40 days following the adoptive transfer. These animals received injection of tumor cells 7 days before the adoptive transfer. A, lung tissue of a mouse which received adoptive transfer of naive CD8⁺ T cells showing a portion of a large tumor (4 mm in diameter) with marked cytologic polymorphism (D). B, lung tissue of a mouse which received adoptive transfer of tumor-reactive control CD8⁺ T cells, which contained the control GFP vector. There are two smaller tumor nodules (0.5 and 0.6 mm in diameter, respectively), which showed some immune cell infiltration and degenerative changes of tumor cells (E). C, lung tissue of a mouse which received adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells. There is a smaller tumor nodule (0.5 mm in diameter). Within this tumor, heavy immune cell infiltrates and marked degenerative changes of tumor cells can be seen (F). This impression was confirmed in Fig. 6A.

acrylamide gel in Tris-HCl (Bio-Rad, Hercules, CA). Electrophoresis was carried out in Tris-glycine-SDS running buffer and transferred to a polyvinylidene difluoride membrane. Blots were probed for phosphorylated *SMAD-2* with a monoclonal antibody. They were then stripped and reprobed for *SMAD-2* and glyceraldehyde-3-phosphate dehydrogenase. Proteins of interest were detected with the enhanced chemiluminescence

detection kit (Amersham Biosciences, Buckinghamshire, United Kingdom) followed by exposure to Kodak X-OMAT AR film.

Plasminogen Activator Inhibitor-1 Promoter-Reporter Activity Assay. CD8⁺ T cells were transiently transfected with a promoter construct, 3TP-Lux, which contains multiple copies of TGF- β response element, using LipofectAMINE 2000 (Invitrogen, Carlsbad, CA). Cells were treated with




Figure 6. A, immunofluorescent staining for nuclei, CD8⁺ T cells, and apoptosis in pulmonary metastasis. Representative tissue sections of pulmonary metastasis from the day 7 group were simultaneously stained for cell nucleus (blue), CD8⁺ T cells (red), and apoptosis (green). Metastatic sites were identified by the nuclear staining (blue). CD8⁺ T cells (red) were identified mainly in the parenchyma of lung tissues not in the tumor with the exception of the TβRIIDN group, in which CD8⁺ T cells (red) were also found within the tumor lesion. Frequent tumor apoptotic sites (green) were only found in the TβRIIDN group. Although few CD8⁺ T cells were found undergoing apoptosis (yellow), the majority of the apoptotic cells were derived from the tumor cells (green). Magnification, $\times 40$. The fate of adoptively transferred CD8⁺ T cells in recipients of different treatment groups. A total of 2×10^6 CD8⁺ T cells were injected via the tail vein into all recipient mice. At designated time intervals, CD8⁺ T cells from the spleen of each animal were isolated. % GFP-positive CD8⁺ T cells was calculated by fluorescent-activated cell sorting. B, % GFP-positive CD8⁺ T cells in the spleen of tumor-free animals. C, % GFP-positive CD8⁺ T cells in the spleen of tumor-bearing animals. A total of 2×10^6 CD8⁺ T cells were tail vein injected into tumor-bearing C57BL/6 mice. % GFP-positive CD8⁺ T cells in the spleen was analyzed by fluorescent-activated cell sorting. Bars, SD. D, circulating levels of IL-2 and IFN- γ in experimental mice. Serum specimens were collected at the time of animals' euthanasia, which is 40 days following the adoptive transfer of CD8⁺ T cells. Serum level of IL-2 in different groups of mice. E, Serum level of IFN- γ in different groups of mice. *, $P < 0.05$; **, $P < 0.01$; and ***, $P < 0.001$. Bars, SD.

10 ng/mL of TGF- β 1 for 16 hours. Luciferase activity was assayed by using an assay kit (Promega, San Diego, CA). Activity was normalized based on β -galactosidase expression with pSV β -galactosidase.

Thymidine Incorporation Assay. CD8⁺ T cells (3×10^4 cells per 24 wells) were treated with or without TGF- β 1 (10 ng/mL) for 16 hours.

A medium containing [3 H]-thymidine (0.5 μ Ci/mL; Amersham Biosciences) was introduced and cells were cultured for additional 5 hours. The experiment was terminated by washing with warm serum-free medium. NaOH (0.1 mol/L) was added to all wells (1 mL). An aliquot of 100 μ L was removed for measurement of the protein content and the remainder

was used for determining the radioactivity. Thymidine incorporation was expressed as the fraction of counts found in controls.

TGF- β 1 ELISA Assay. TRAMP-C2 cells (1.0×10^7 per T75 flask) were cultured in serum-free media for 24 hours. The medium was replaced for 24 hours. The pooled conditioned medium was collected and concentrated by using YM-3 Centriprep Centrifugal Filter Devices (Millipore Co., Bedford, MA). After activation of TGF- β 1 by treatment with 1 N HCl (0.1 mL per 0.5 mL per conditioned media), the mixture was neutralized by 0.1 mL 1.2 N NaOH/0.5 mol/L HEPES. The ELISA assay was carried out using the Quantikine Human TGF- β 1 Immunoassay Kit from R&D Systems (Minneapolis, MN). The total number of cells in each flask was counted using a Coulter Counter and levels of TGF- β 1 were reported as pg per 10^5 cells per 48 hours.

Fate of Tumor-Reactive CD8 $^+$ T Cells in the Spleen. Because tumor-reactive CD8 $^+$ T cells are labeled with GFP, the percent of GFP positive CD8 $^+$ T cells in the spleen was determined by flow cytometry. This experiment was carried out in both tumor-free animals and in tumor-bearing animals at different time points.

Statistical Methods. All *in vitro* experiments were done in triplicate. Numerical data were expressed as mean \pm SD. ANOVA and multiple range test were done to determine differences of means among different treatment groups. $P < 0.05$ was considered statistically significant. The SPSS 10.0.7 software package (SPSS, Inc., Chicago, IL) was used for analysis. Kaplan-Meier survival curve was analyzed by the log-rank test using the Graphpad Prism 4.02 software (Graphpad Software, Inc., San Diego, CA).

Results

TGF- β 1 Production in TRAMP-C2 Cells. TRAMP-C2 cells secreted 170 pg TGF- β 1 in 10^5 cells over 48 hours. For comparison, TGF- β 1 production was measured in other murine cell lines (B16, Renca), human cancer cell lines (LNCaP, PC3, and TSU-Pr1) and a benign human prostate epithelial line, RWPE-1 (Fig. 1A).

Status of TGF- β Signaling in CD8 $^+$ T Cells. Under normal conditions, CD8 $^+$ T cells expressed high levels of type I and type II TGF- β receptors (Fig. 1B) and they are highly sensitive to the inhibitory effect of TGF- β (12). When CD8 $^+$ T cells were infected with the retrovirus containing T β RIIDN, they became insensitive to TGF- β , as shown by following tests. T β RIIDN infected CD8 $^+$ T cells were insensitive to TGF- β 1 by a lack of SMAD-2 phosphorylation, which was observed in naive CD8 $^+$ T cells or cells infected with GFP control vector (Fig. 2C). Similarly, there was a significant inhibition of plasminogen activator inhibitor-1 promoter-luciferase reporter activity in TGF- β -insensitive CD8 $^+$ T cells in response to TGF- β 1 (Fig. 2D). Finally, these cells were insensitive to TGF- β 1-mediated inhibition of thymidine incorporation assay (Fig. 2E).

***In vitro* Antitumor Activity of Tumor-Reactive TGF- β -Insensitive CD8 $^+$ T Cells.** Tumor-reactive TGF- β -insensitive CD8 $^+$ T cells showed a potent-specific lysis against TRAMP-C2 cells (Fig. 3A). These cells showed a 5-fold more tumor-killing activity than that of TGF- β -sensitive counterpart and 25-fold over that of naive CD8 $^+$ T cells. Both the TGF- β -sensitive and TGF- β -insensitive tumor-reactive CD8 $^+$ T cells showed a reduced tumor-killing activity when incubated with an irrelevant cell line, mouse B16-F10 melanoma cells (Fig. 3B).

***In vivo* Antitumor Activity of Tumor-Reactive TGF- β -Insensitive CD8 $^+$ T Cells.** In the absence of any intervention, at 21 days following the injection of tumor cells, multiple pulmonary gross and microscopic pulmonary metastases were evident (data not shown). Those animals which received adoptive

transfer of tumor-reactive TGF- β -insensitive CD8 $^+$ T cells had the least degree of tumor burden (Fig. 4A and B). There was no evidence of pulmonary metastasis in the group of mice which received adoptive transfer at 3 days following the injection of tumor cells. One of 10 animals in the 7-day group was found to have microscopic evidence of pulmonary metastasis at the time of sacrifice. Two of nine animals in the 21-day group must be sacrificed earlier due to poor health conditions and were found to have pulmonary metastasis of the tumor. Animals which received adoptive transfer of tumor-reactive control CD8 $^+$ T cells (GFP only) showed an intermediate degree of tumor burden; whereas those which received adoptive transfer of naive CD8 $^+$ T cells were ineffective in inhibiting tumor progression. Analysis of Kaplan-Meier survival curve showed highly significant differences among three treatment groups (Fig. 4C).

Histologic Findings. The most prominent histologic feature of the tumor tissue in this study is the evidence of infiltration of CD8 $^+$ T cells into the tumor tissue and the presence of apoptosis in tumor cells of animals which received adoptive transfer of tumor-reactive TGF- β -insensitive CD8 $^+$ T cells (the T β RIIDN group; Fig. 6A). Tumors in animals of the other two groups showed little or no CD8 $^+$ T cells and showed no evidence of apoptosis in tumor cells (Fig. 6A). CD8 $^+$ T cells, however, are present in the parenchymal tissue of the lung in animals of all groups (Fig. 6A). Although CD8 $^+$ T cells were not observed in tumors of animals in the GFP group, immune cell infiltration was apparent according to histologic observation (Fig. 5E), but such immune cell infiltration was more prominent in tumor of the T β RIIDN group (Fig. 5F). No immune cell infiltration was noted in tumors of animals which received adoptive transfer of naive CD8 $^+$ T cells (Fig. 5D).

Another feature is the lack of infiltration of immune cells in the air space of the lung in all animals, including those which received adoptive transfer of tumor-reactive TGF- β -insensitive CD8 $^+$ T cells (Fig. 5). This is in sharp contrast to our earlier studies, in which recipient animals which received TGF- β -insensitive bone marrow transplant and developed massive infiltration of immune cells in the air space of the lung (19, 20). In the present study, the air space was devoid of any immune cells, suggesting that autoimmune disease was not apparent in these animals.

Fate of Transferred CD8 $^+$ T Cells. In the present study, a total of 2×10^6 CD8 $^+$ T cells were transferred into each recipient animal. This number was derived by extrapolating the comparable number of T cells in adoptive therapy for cancer patients (1, 6). In a similar study with adoptive transfer of experimental melanoma model, 3×10^6 antigen-specific T cells were used (21). To determine the fate of these transferred cells, we measured the percentage of GFP-positive CD8 $^+$ T cells in the spleen of recipient animals. When CD8 $^+$ T cells were adoptively transferred to tumor-free hosts, there was a linear decay in GFP-positive CD8 $^+$ T cells reaching 0% by 30 days for tumor-reactive CD8 $^+$ T cells infected with the GFP control vector and 50 days for tumor-reactive CD8 $^+$ T cells infected with the T β RIIDN vector (Fig. 6B). However, when tumor-reactive TGF- β -insensitive CD8 $^+$ T cells were adoptively transferred to tumor-bearing hosts (the T β RIIDN group), the percentage of GFP-positive CD8 $^+$ T cells was maintained at 2% for at least 40 days; whereas in animals which received adoptive transfer of tumor-reactive control CD8 $^+$ T cells (the GFP group), GFP-positive CD8 $^+$ T cells showed a decay curve similar to that in tumor-free hosts with a slight delay (Fig. 6C).

Serum Levels of IFN- γ and IL-2. In animals which received adoptive transfer of naive CD8⁺ T cells, there was a baseline level of IL-2 and IFN- γ . In animals which received tumor-reactive control CD8⁺ T cells (the GFP group), there was a significant increase in both cytokines. A further increase in serum IL-2 (Fig. 6D) and IFN- γ (Fig. 6E) was observed when these cells were rendered insensitive to TGF- β (the T β RIIDN group), suggesting the presence of activated immune cells in these hosts.

Discussion

Immunotherapy using adoptive transfer of immune cells is a promising approach for treatment of cancer patients. However, currently available therapies have not achieved a significant number of complete responders. A successful adoptive therapy for cancer should be the development of robust effector cells with specific antitumor efficacy. At the same time, the treatment will overcome the tumor-derived immunosuppressive effect.

A significant part of tumor immunology has focused on the identification of tumor-specific antigens and the cytolytic T cells specific for these peptides (22). Adoptive T-cell therapy using antigen-specific CD8⁺ T cells for cancer treatment has been attempted with some degree of success (5, 23) and seems to be an advantage over the transfer of nonspecific T cells (21). Results of the present study have shown that adoptive transfer of tumor-reactive and TGF- β -insensitive CD8⁺ T cells were able to specifically target against autologous tumor cells and eradicate established pulmonary metastasis. The use of tumor-specific adoptive immunotherapy has reported before and has clearly shown its efficacy by other investigators (23, 24). The critical issue in immunotherapy thus far has been the tumor-derived immunosuppressive effect, which remains unresolved.

The mouse prostate cancer model, TRAMP-C2, represents an aggressive line of malignant cells, which secrete large amounts of TGF- β . The role of immunosuppressive effect of TGF- β in cancer progression has been well established (13, 25–27). In the present study, we have shown that, TRAMP-C2 tumors possess potent immunosuppressive power so that regular CD8⁺ T cells are unable to infiltrate into the tumor tissues. However, if these tumor-reactive CD8⁺ T cells are engineered and rendered insensitive to TGF- β , they are able to infiltrate into the tumor tissue and induce apoptosis in these established TRAMP-C2 tumors. To the best of our knowledge, studies to test this concept have not been attempted before. These results support the concept that TGF- β is an important target in cancer therapy.

Results of the present study show that in tumor-bearing hosts, the transferred CD8⁺ T cells persist, only if they are tumor reactive and TGF- β insensitive. Therefore, adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells will persist in tumor-bearing hosts and does not require the procedure of lymphodepletion. Interestingly, these cells decayed in tumor-free hosts. Accompanied with the persistence of these transferred CD8⁺ T cells were elevated circulating levels of IL-2 and IFN- γ , a critical requirement for antitumor activity in the host (24). Therefore,

with our current approach of adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells, exogenous treatment of IL-2 is not necessary for a successful antitumor activity. On the other hand, naive CD8⁺ T cells and tumor-reactive CD8⁺ T cells but sensitive to TGF- β did not persist in the host, suggesting that these cells failed to establish an engraftment regardless the status of the presence or absence of tumor cells in the host. These observations suggest that a single transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells is sufficient for tumor rejection.

Our results also indicate that CD8⁺ T cells contain high levels of TGF- β receptor types I and II and therefore, are highly sensitive to the inhibitory effects of TGF- β . The role of TGF- β in the immune system is best shown in TGF- β knockout animals. Mice lacking TGF- β , although they grew normally for the first 2 weeks, develop rapid wasting syndrome, and die by 3 to 4 weeks of age (28, 29). These studies showed a powerful immunoregulatory role of TGF- β because TGF- β ^{-/-} mice had excessive inflammatory responses with massive infiltration of lymphocytes and macrophages in multiple organs. These syndromes were characterized as autoimmunity (17, 29). Results of our past study have shown that mice receiving TGF- β -insensitive bone marrow transplants have met with the same fate by developing autoimmune syndrome, although these animals were able to eliminate challenged tumors (19, 20). In the present study, the use of the tumor-specific TGF- β -insensitive CD8⁺ T cells for the treatment of established cancer did not result in the development of massive infiltration of immune cells into the airspace of the lung of tumor-bearing host and, in tumor-free hosts, these CD8⁺ T cells failed to persist in the host. These preliminary observations seem to suggest an apparent absence of the development of autoimmune disease in these animals. Further studies are warranted to verify this impression.

In summary, the present results showed that adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells to tumor-bearing hosts was able to eradicate autologous tumors. These CD8⁺ T cells have the following characteristic properties. First, they are specifically reactive against tumor tissues. Second, they are insensitive to TGF- β . These two properties endowed these CD8⁺ T cells with the ability to infiltrate into tumor tissues and function as potent effectors against tumor cells. Finally, these cells are able to persist in tumor-bearing hosts but not in tumor-free hosts. These findings provide a proof of principle that an adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells may warrant consideration for the treatment of advanced cancers.

Acknowledgments

Received 9/2/2004; revised 11/11/2004; accepted 12/14/2004.

Grant support: Department of Defense grants PC970410, PC001491, and PC030038 and National Cancer Institute grants CA90386 and CA107186.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References

1. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. *Nat Rev Cancer* 2003;3:666–75.
2. Rosenberg SA, Lotze MT, Muul LM, et al. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. *Surgery* 1986;100:262–72.
3. Economou JS, Beldegrun AS, Glaspy J, et al. *In vivo* trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. *J Clin Invest* 1996;97:515–21.

4. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. *J Clin Oncol* 1999;17:2521-9.
5. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8⁺ T cells clones for the treatment of patients with metastatic melanoma: *In vivo* persistence, migration, and antitumor effect of transferred T cells. *Proc Natl Acad Sci U S A* 2002;99:16168-73.
6. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. *Proc Natl Acad Sci U S A* 2004;101 Suppl 2:14639-45.
7. Rosenberg SA. Development of effective immunotherapy for the treatment of patients with cancer. *J Am Coll Surg* 2004;198:685-96.
8. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. *J Immunother* 1997;20:165-77.
9. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. *Nat Immunol* 2002;3:999-1005.
10. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. *J Exp Med* 1993;177:265-72.
11. Li J, Hu P, Khawli LA, Epstein AL. Complete regression of experimental solid tumors by combination LEC/chTNF-3 immunotherapy and CD25⁺ T-cell depletion. *Cancer Res* 2003;63:8384-92.
12. Letterio JJ, Roberts AB. Regulation of immune responses by TGF- β . *Ann Rev Immunol* 1998;13:51-69.
13. Matthews E, Yang T, Janulis L, et al. Down regulation of TGF- β 1 production restores immunogenicity in prostate cancer cells. *Brit J Cancer* 2000;83:519-25.
14. Torre-Amione G, Beauchamp RD, Koeppen H, et al. A highly immunogenic tumor transfected with a murine transforming growth factor type β 1 cDNA escapes immune surveillance. *Proc Natl Acad Sci U S A* 1990;87:1486-90.
15. de Visser KE, Kast MW. Effects of TGF- β on the immune system: implications for cancer immunotherapy. *Leukemia* 1999;13:1188-99.
16. Fortunel NO, Hatzfeld A, Hatzfeld J. Transforming growth factor- β : pleiotropic role in the regulation of hematopoiesis. *Blood* 2000;96:2022-36.
17. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor- β signaling in T cells. *Nat Med* 2001;7:1118-22.
18. Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ. Tumor-derived TGF- β reduces the efficacy of dendritic cell/tumor fusion vaccine. *J Immunol* 2003;170:3806-11.
19. Shah AH, Tabayoyong WB, Kim SJ, van Parijs L, Kimm S, Lee C. Reconstitution of lethally irradiated mice with TGF- β insensitive bone marrow leads to myeloid expansion and inflammatory disease. *J Immunol* 2002;169:3485-91.
20. Shah AH, Tabayoyong WB, Kundu SD, et al. Suppression of tumor metastasis by blockade of TGF- β signaling in bone marrow cells through a retroviral mediated gene therapy in mice. *Cancer Res* 2002;62:7135-8.
21. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigen demonstrate superior *in vitro* and *in vivo* antitumor efficacy. *J Immunol* 1999;162:989-94.
22. van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. *Curr Opin Immunol* 1997;9:684-93.
23. Ho WY, Yee C, Greenberg PD. Adoptive therapy with CD8⁺ T cells: it may get by with a little help from its friends. *J Clin Invest* 2002;110:1415-7.
24. Finkelstein SE, Heimann DM, Klebanoff CA, et al. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. *J Leukoc Biol* 2004;76:333-7.
25. Chen TC, Hinton DR, Yong VW, Hofman FM. TGF- β 2 and soluble p55 TNFR modulate VCAM-1 expression in glioma cells and brain derived endothelial cells. *J Neuroimmunol* 1997;73:155-61.
26. Xu J, Menezes J, Prasad U, Ahmad A. Elevated serum transforming growth factor β 1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM. *J Virol* 2000;74:2443-6.
27. Abou-Shady M, Baer HU, Friess H, et al. Transforming growth factor β s and their signaling receptors in human hepatocellular carcinoma. *Am J Surg* 1999;177:209-15.
28. Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor-1 null mutation in mice causes excessive inflammatory response and early death. *Proc Natl Acad Sci U S A* 1993;90:770-4.
29. Yaswen L, Kulkarni AB, Fredrickson T, et al. Autoimmune manifestations in the transforming growth factor- β 1 knockout mouse. *Blood* 1996;87:1439-45.

Infiltration of Tumor-Reactive Transforming Growth Factor-Beta Insensitive CD8⁺ T Cells Into the Tumor Parenchyma is Associated With Apoptosis and Rejection of Tumor Cells

Qiang Zhang,¹ Thomas L. Jang,¹ Ximing Yang,² Irwin Park,¹ Shilajit Kundu,¹ Michael Pins,² Borko Javonovic,³ Timothy Kuzel,⁴ Seong-Jin Kim,⁵ Luk Van Parijs,⁶ Norm Smith,¹ Larry Wong,¹ Norman M. Greenberg,⁷ Yinglu Guo,⁸ and Chung Lee^{1*}

¹Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

²Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

³Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois

⁴Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois

⁵Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland

⁶Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts

⁷Fred Hutchinson Cancer Research Center, Seattle, Washington

⁸Institute of Urology, The First Hospital, Peking University, Beijing, China

BACKGROUND. TGF- β is a potent immunosuppressant. High levels of TGF- β produced by cancer cells have a negative inhibition effect on surrounding host immune cells and leads to evasion of the host immune surveillance and tumor progression. In the present study, we report a distinct ability of tumor reactive, TGF- β -insensitive CD8⁺ T cells to infiltrate into established tumors, secrete relevant cytokines, and induce apoptosis of tumor cells.

METHODS. CD8⁺ T cells were isolated from the spleens of C57BL/6 mice, which were primed with irradiated mouse prostate cancer cells, the TRAMP-C2 cells. After ex vivo expansion, these tumor reactive CD8⁺ cells were rendered TGF- β -insensitive by infection with a retroviral (MSCV)-mediated dominant negative TGF- β type II receptor (T β RIIDN). Control CD8⁺ cells consist of those transfected with the GFP-only empty vector and naïve CD8⁺ T cells. Recipient mice were challenged with a single injection of TRAMP-C2 cells 21 days before adoptive transfer of CD8⁺ T cells was performed. Forty days after the adoptive transfer, all animals were sacrificed. The presence of pulmonary metastases was evaluated pathologically. Serial slides of malignant tissues were used for immunofluorescent staining for different kinds of immune cell infiltration, cytokines, and apoptosis analysis.

Abbreviations: TGF- β , transforming growth factor beta; GFP, green fluorescent protein; T β RIIDN, dominant-negative type II TGF- β receptor; TRAMP, transgenic adenocarcinoma of the mouse prostate; IFN- γ , interferon-gamma; IL-2, interleukin-2; NO, nitric oxide; TNF- α , tumor necrosis factor-alpha; PCNA, proliferating cell nuclear antigen; NK, natural killer cells; TR, Texas red; FITC, fluorescein isothiocyanate.

The authors declare that they have no competing financial interests.

Grant sponsor: Department of Defense; Grant numbers: PC970410, PC001491, PC030038; Grant sponsor: National Cancer Institute; Grant number: CA107186.

*Correspondence to: Chung Lee, PhD, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Tarry 16-733, Chicago, IL 60611. E-mail: c-lee7@northwestern.edu
Received XXXXX^{Q1}; Accepted XXXXX
DOI 10.1002/pros.00000
Published online 00 Month 2005 in Wiley InterScience (www.interscience.wiley.com).

RESULTS. Pulmonary metastases were either eliminated or significantly reduced in the group receiving adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells (3 out of 12) when compared to GFP controls (9 out of 12), and naïve CD8⁺ T cells (12 out of 12). Results of immunofluorescent studies demonstrated that only tumor-reactive TGF- β -insensitive CD8⁺ T cells were able to infiltrate into the tumor and mediate apoptosis when compared to CD4⁺ T cells, NK cells, and B cells. A large amount of cytokines such as perforin, nitric oxide, IFN- γ , IL-2, TNF- α were secreted in tumor tissue treated with tumor-reactive TGF- β -insensitive CD8⁺ T cells. No immune cells infiltration and cytokine secretion were detected in tumor tissues treated with naïve T cells and GFP controls.

CONCLUSIONS. Our results demonstrate the mechanism of anti-tumor effect of tumor-reactive TGF- β -insensitive CD8⁺ T cells that adoptive transfer of these CD8⁺ T cells resulted in infiltration of these immune cells into the tumor parenchyma, secretion of relevant cytokines, and induction of apoptosis in tumor cells. These results support the concept that tumor-reactive TGF- β -insensitive CD8⁺ T cells may prove beneficial in the treatment of advanced cancer patients. *Prostate* 9999: 1–14, 2005. © 2005 Wiley-Liss, Inc.

KEY WORDS: TGF- β ; adoptive transfer; gene therapy; CD8⁺ T cell; immunosurveillance; tumor rejection

INTRODUCTION

Immunotherapy using adoptive transfer of immune cells is a promising approach for treating cancer patients. The presence of tumor infiltrating lymphocytes (TIL) in the tumor parenchyma has been recognized for three decades [1]. TIL were isolated from surgical specimens, clonally expanded *ex vivo*, and adoptively transferred to cancer patients with variable results [2,3]. Recently, Yee and coworkers selected antigen-specific CD8⁺ T cells for *ex vivo* expansion and transferred these cells into patients. However, these CD8⁺ T cells did not persist, requiring repeated transfers of CD8⁺ T cells in order to elicit clinical responses [4]. Rosenberg and colleagues treated autologous TIL cells with IL-2 for *ex vivo* expansion and then transferred them to patients. Again, in order for these cells to "engraft," lymphodepletion was necessary [5]. These results, although impressive, seem to suggest a missing element in adoptive transfer of CD8⁺ T cells for the treatment of cancer.

The functional role of TIL in cancer therapy has been a subject of controversy [6]. Initially, it appeared that the presence of TIL in tumors could correlate to prognosis [7]. Subsequent studies showed that TIL were functionally impaired [8–10] from effects exerted by the tumor microenvironment [11]. The development of an immune-based strategy for cancer therapy must take into account not only immune stimulation, but also the issue of overcoming tumor-derived immune suppression [12]. Among many immunosuppressants, TGF- β is a potent and important player [13–18].

High levels of TGF- β produced by cancer cells have a negative effect on surrounding cells such as the host immune cells and have been implicated to play a role in tumor escape from immune surveillance [19,20]. Besides the tumor, the immune system, in response to

the presence of tumor, is also able to produce a significant amount of TGF- β to down-regulate immune surveillance [21].

TGF- β , therefore, appears to be an attractive target for anti-cancer therapy. Investigators have attempted to utilize the properties of TGF- β advantageously for the treatment of cancer. Gorelik and Flavell [17] first described the immune-mediated eradication of tumors through the blockade of TGF- β signaling in T cells. These investigators used transgenic mice with TGF- β null expression targeted specifically to T cells. Subsequently, our study using transplant of TGF- β -insensitive bone marrow cells also demonstrated a total rejection of metastatic tumor cells [22,23]. However, autoimmune disease eventually developed in the hosts in both studies due to the non-specific nature of the immune cells. More^{Q2} recently, we have shown that adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells, which have high specific tumor killing ability and were able to eradicate established lung metastases of mouse prostate cancer cells, TRAMP-C2, which secreted large amounts of TGF-beta [24]. In the present study, we conducted additional experiments to delineate the mechanism of the tumoricidal ability of tumor-reactive TGF- β -insensitive CD8⁺ T cells. We report a distinct ability of these CD8⁺ T cells to infiltrate into established tumors, secrete relevant cytokines, and induce apoptosis of tumor cells.

MATERIALS AND METHODS

Mice and Cells

Male C57BL/6 mice of 6–8 weeks of age were purchased from Jackson Laboratories (Bar Harbor, ME) and maintained in pathogen-free facilities at the Center for Comparative Medicine at Northwestern University

Feinberg School of Medicine in accordance with the established guidelines of the Animal Care and Use Committee of Northwestern University. TRAMP-C2 is an early-passage murine prostate cancer cell line derived from TRAMP mice that spontaneously develops prostate cancer due to prostate-specific simian virus 40 (SV 40) large T tumor antigen (Tag) expression. Cells were cultured in RPMI-1640 medium (GIBCO, Rockville, MD) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, and 100 μ g/ml streptomycin (GIBCO).

Generation of Tumor-Reactive TGF- β -Insensitive CD8⁺ T Cells

Ex vivo expansion of tumor-reactive CD8⁺ T cells from the splenocytes: Male C57BL/6 mice were primed with irradiated TRAMP-C2 cells (5×10^6 /mice at 20,000 ci) by subcutaneous injection every 14 days for a total of five inoculations. Two weeks following the last vaccination, CD8⁺ T cells from the spleen were isolated by using murine T cell CD8 subset column kit (R&D Systems, Minneapolis, MN). CD8⁺ T cells (10^5 /ml) were cultured in the presence of TRAMP-C2 lysates (1×10^6 /ml) and irradiated mouse splenocytes (1×10^6 /ml at 3,000 ci) in medium containing RPMI-1640 with 10% FBS, IL-2 (50 U/ml, R&D), CD3⁺ monoclonal antibody (30 ng/ml, R&D), HEPE (25 mM), L-glutamine (4 mM), and 2-ME (25 mM) (Sigma, St. Louis, MO) at 37°C and under 5% CO₂. Culture media were changed every 3 days. CD8⁺ T cells were cultured for around 10 weeks before they were infected with a retrovirus containing dominant negative TGF- β type II receptor (T β RIIDN-GFP) vector or the control GFP only vector. Rendering insensitivity to TGF- β by infection with T β RIIDN-GFP-containing retrovirus: Construction of the mouse stem cell retroviral vector (MSCV) containing the dominant negative TGF- β type II receptor (T β RIIDN) and green fluorescent protein (GFP) was performed as previously described [22,23]. Tumor-reactive CD8⁺ T cells above were infected with retroviral particles containing T β RIIDN-GFP or GFP only via spin infection as described earlier [22,23]. Infection efficiency was assessed for GFP expression by flow cytometry, only the infection efficiency was up to 90%, the cells could be used for adoptive transfer that was performed 72 hr after infection.

Tumor Bearing Animal Survival Analysis

Male C57BL/6 mice were challenged i.v. with 5×10^5 TRAMP-C2 cells. Twenty-one days later, they received adoptive transfer of one of the three groups of CD8⁺ T cells (2×10^6). CD8⁺ T cells in Group 1 were tumor-reactive TGF- β -insensitive CD8⁺ T cells infected with the T β RIIDN-GFP viral particles. Those in Group 2

were tumor reactive CD8⁺ T cells infected with the GFP-only control vectors. Cells in Group 3 were naïve CD8⁺ T cells. Forty days after CD8⁺ T cells transfer, mice were sacrificed by cervical dislocation. Some animals were sacrificed earlier than 40 days due to poor health conditions. The lung from each animal was isolated for gross and histological examination. At 40 days, all animals were inspected for the presence of pulmonary metastases. The time of sacrifice for mice in each group was compared by the Kaplan–Meier method. The pulmonary specimens were prepared as serial sections with 4 μ m for each through the whole lungs.

Immunohistochemical Staining

H&E staining: Upon euthanasia, the lung from each animal was excised, fixed in formalin, embedded in paraffin, and serially sectioned at 4 μ m thick until the embedded tissue was exhausted. Routine Hematoxylin & Eosin (H&E) staining was performed at an interval of every five serial sections. All H&E sections were evaluated for the presence of tumor tissues by at least three independent investigators. PCNA immunological staining: VECTASTAIN ABC kit (Vector Labs, Burlingame, CA) was used according to the procedure from the manufacturer with the following adjustment: after deparaffinization, quenching of endogenous peroxidase activity and normal serum pre-blocking, the sections were incubated in diluted mouse monoclonal PCNA antibody (1:100, Upstate, Lake Placid, NY) for 2 hr in room temperature, followed by incubation with biotinylated goat horse anti-mouse secondary antibody (1:200, Vector Labs) for 2 hr. Then peroxidase substrate solution DAB (DAKO Corporation, Carpinteria, CA) was used for desired staining and Harris Hematoxylin Solution for counterstaining.

Immunofluorescent co-Staining for Infiltration of Immune Cells and Secretion of Cytokines

Unstained paraffin-embedded serial sections of metastatic cancer to the lung were used for immunofluorescent staining to detect infiltration of immune cells (CD8⁺ T, CD4⁺ T, B cells, and NK cells) and secretion of cytokines (perforin, Nitric Oxide, IFN- γ , TNF- α , IL-2). The methods of immunofluorescent co-staining were performed by using the assay as previously described [24]. (A): Expression of TGF- β in tumor tissue was analyzed by using Nuclear-TGF- β 1 double staining; (B): Infiltration of immune cells in tumor tissue was analyzed by Nuclear-immune cells double staining. Mouse CD8⁺ T cells, CD4⁺, NK(NCAM) cells, B (BLCAM) cells were evaluated, respectively; (C): Identification of the source of CD8⁺ T cells in tumor tissue: Nuclear-CD8⁺-GFP protein triple staining; (D): Secretion of cytokines were analyzed by:

Nuclear-CD8⁺-cytokines triple staining. Expression of perforin, Nitric Oxide, IFN- γ , TNF- α , IL-2 were analyzed. The parameters of the antibodies (Santa Cruz, Santa Cruz, CA) are listed in Table I. All the slides were deparaffinized and blocked by normal serum. The sections were then incubated with the fluorescent staining as described before [23]. All the slides were stained with VECTASHIELD mounting media (blue) (Vector lab) for nuclear counterstaining. Staining was viewed with Nikon TE2000-U fluorescent microscopy (Nikon Corporation, Tokyo, Japan). Images were digitized by Photoshop 7.0 with a PC computer. The intensity of the fluorescent signal was standardized by the standard fluorescent index (positive lymphocytes or signal/100 tumor cells/1,000 μm^2): - : <5; \pm : 6–10; + : 11–30; ++ : 31–50; +++ : 51–70; ++++ : >70.

Immune-Mediated Tumor Apoptosis Assay

Following deparaffinizing, tissue sections were subjected to apoptosis assay by using the TUNEL apoptosis kit (Upstate, Lake Placid, NY) according to the recommendations of the manufacturer. Briefly, the slides were treated with Proteinase K for 30 min at 37°C, incubated with TdT end-labeling cocktail (TdT Buffer, Biotin-dUTP, and TdT, at a ratio of 90:5:5) for 120 min at 37°C followed by Avidin-FITC (green) solution (50 μl), incubated in the dark for 60 min at 37°C. Slides were then incubated with 50 μl of blocking buffer at room temperature for 20 min followed by rat monoclonal antibody for CD8⁺ labeled with TR (red) (2 $\mu\text{g}/\text{ml}$, Santa Cruz) in the dark for 30 min at room temperature. Finally, slides were washed with PBS and stained with VECTASHIELD mounting media (blue) (Vector lab) for nuclear staining. They were viewed with Nikon TE2000-U fluorescent microscopy (Nikon Corporation, Tokyo, Japan). Images were digitized by Photoshop 7.0 with a PC computer.

Statistical Analysis

Analysis of variance and multiple range tests were performed to determine differences of means among different treatment groups. A *P*-value of less than 0.05 was considered statistically significant. SPSS 10.0.7 software package (SPSS Inc.) was used for analysis. Kaplan–Meier survival curve was analyzed by the log-rank test using the Graphpad Prism 4.02 software (Graphpad Software Inc., San Diego, CA).

RESULTS

In Vivo Anti-Tumor Activity of Tumor Reactive, TGF- β -Insensitive CD8⁺ T Cells

To demonstrate the in vivo anti-tumor activity, male C57BL/6 mice of 6–8 weeks old were challenged with

5×10^5 TRAMP-C2 cells by intravenous injections for 21 days. In the absence of any intervention, at 21 days following tumor cell challenge, multiple gross and microscopic pulmonary metastases were evident. All animals were sacrificed 40 days following CD8⁺ T cells transfer, or sooner due to poor health conditions. Mice who received tumor-reactive, TGF- β -insensitive CD8⁺ T cells had the least degree of tumor burden. Nine of 12 animals were free of pulmonary metastasis (Fig. 1A) and 3 mice with metastasis had an average number of metastasis per animal (number \pm SD) of 1.67 ± 0.5 . Animals who received tumor reactive control CD8⁺ T (GFP only) cells showed partial anti-tumor activity with 3 out of 12 animals showing tumor-free and those with metastasis had an average number of metastasis per animal (number \pm SD) of 3.7 ± 1.1 . Adoptive transfer of naïve CD8⁺ T cells was ineffective in inhibiting tumor progression. All animals in the group had pulmonary metastasis with the average number of metastasis per animal (number \pm SD) being 4.8 ± 1.5 . Results of Kaplan–Meier analysis showed significant survival differences among the three treatment groups (Fig. 1B).

Histological Findings

The H&E stained sections of tumors that metastasized to the lung were evaluated (Fig. 2A,C,E with magnification of 100 \times ; 2B, 2D, and 2F with a magnification of 400 \times). In tumors from animals who received naïve CD8⁺ T cells, a portion of a large tumor (Fig. 2A and 3 mm in diameter) with marked cytological polymorphism (Fig. 2B) is illustrated. In the mouse who received adoptive transfer of tumor-reactive control CD8⁺ T cells (GFP only), there is one smaller tumor nodule (Fig. 2C, 1.5 mm in diameter), which demonstrates some infiltration and degenerative changes of tumor cells (Fig. 2D). In the tumor from mice who received adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells (T β RIIDN), there is a smaller tumor nodule (Fig. 2E, 0.5 mm in diameter) with heavy lymphocytic infiltrates and marked degenerative changes of tumor cells (Fig. 2F). Another feature is the lack of infiltration of immune cells in the air spaces of the lung in all animals, including those who received adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells, suggesting that autoimmune disease was not apparent in these animals. This contrasts to our earlier study in which recipient animals who received TGF- β insensitive bone marrow transplant developed massive infiltration of immune cells in the air spaces of the lung [22,23].

A tumor nodule in a mouse who received naïve CD8⁺ T cells, composed of tumor cells with high proliferative activity (>80% cells positive for PCNA) is shown in Figure 2G,H. In animals who received

TABLE I. Antibodies for Immunofluorescent Staining

A. Nuclear-TGF- β 1 double staining				
TGF- β 1 staining			Nuclear staining	
TGF- β 1	Primary antibody	Secondary antibody	VECTASHIELD mounting medium with DAPI	
	Polyclonal-rabbit-mouse, 1: 100, 2 hr	Goat-rabbit-FITC, 1:300, 2 hr		
B. Nuclear- immune cells double staining				
CD8+ T cells (CD8-2.43) CD4+ T cells (CD4-RM4 5) B cells (BLCAM-H221) NK cells (NCAM-H300)	Immune cells staining		Nuclear staining	
	Monoclonal-rabbit-mouse-FITC, 1:300, 2 hr		VECTASHIELD mounting medium with DAPI	
	Monoclonal-rabbit-mouse-FITC, 1:300, 2 hr			
	Monoclonal-rabbit-mouse-FITC, 1:300, 2 hr			
	Monoclonal-rabbit-mouse-FITC, 1:300, 2 hr			
C. Nuclear-CD8 ⁺ -GFP protein triple staining				
Monoclonal mouse Ig G-rhodamine 1:100, 2 hr/RT	GFP		Nuclear staining	
	Monoclonal-rat-mouse-FITC 1:100, 2 hr/RT		VECTASHIELD mounting medium with DAPI	
D. Nuclear-CD8 ⁺ - cytokines triple staining				
Perforin IFN- γ Nitric oxide IL-2 TNF- α	Cytokines staining		CD8 ⁺ staining	Nuclear staining
	Primary antibody	Secondary antibody		
	Polyclonal-rabbit-mouse, 1:100, 2 hr	Goat-rabbit-FITC, 1:500, 2 hr	Monoclonal-rat-mouse-TR, 1:100, 2 hr	VECTASHIELD
	Polyclonal-goat-mouse, 1:150, 2 hr	Donkey-goat-FITC, 1:250, 1.5 hr	Monoclonal-rat-mouse-TR, 1:100, 2 hr	mounting medium
	Monoclonal-mouse-mouse, 1:100, 2 hr	Goat-mouse- TR, 1:500, 2 hr	Monoclonal-mouse-mouse-FITC, 1:100, 2 hr	with DAPI
	Polyclonal-rabbit-mouse, 1:100, 2 hr	Goat-rabbit-FITC, 1:300, 2 hr	Monoclonal-rat-mouse-TR, 1:100, 2 hr	
	Polyclonal-rabbit-mouse, 1:100, 1 hr	Goat-rabbit-FITC, 1:300, 2 hr	Monoclonal-rat-mouse-TR, 1:100, 2 hr	




Fig. 1. In vivo anti-tumor activity of tumor reactive TGF- β -insensitive CD8⁺ T cells. **A:** Status of pulmonary metastasis of TRAMP-C2 tumors in mice received adoptive transfer of CD8⁺ T cells. There are three types of CD8⁺ T cells: Naïve CD8⁺ T cells were CD8⁺ T cells isolated from spleens of untreated C57BL/6 mice, tumor-reactive control CD8⁺ T cells (GFP), and tumor-reactive TGF- β -insensitive CD8⁺ T cells (TβRIIDN). TRAMP-C2 cells (5×10^5) were challenged to recipient mice. At 21 days following tumor challenge, animals were sacrificed at 40 days following the adoptive transfer or sooner due to poor health conditions. Representative gross feature of lung tissues from tumor-bearing mice at 40 days following tumor challenge. Arrows indicate metastatic sites. **B:** Kaplan-Meier survival curve of tumor-bearing mice received adoptive transfer of naïve CD8⁺ T cells, GFP-infected CD8⁺ T cells, and TβRIIDN-infected CD8⁺ T cells. $P < 0.05$ by the log-rank test for the TβRIIDN group versus the naïve group or GFP group.

tumor-reactive control CD8⁺ T cells (the GFP group), the majority of tumor cells show high proliferative activity (>80% cells positive for PCNA) (Fig. 2I,J). On the contrary, the degenerative tumor cells in mice receiving tumor-reactive TGF- β -insensitive CD8⁺ T cells show low proliferative activity (<10% cells positive for PCNA). (Fig. 2K,L). There is no statistic difference between naïve group and GFP group, but there is a significant difference between TβRIIDN groups and the above two groups ($P < 0.05$).

Infiltration of Tumor-Reactive TGF- β -Insensitive CD8⁺ T Cells in Tumor Tissue

The most prominent histological feature of the tumor tissue in this study is evidence of infiltration of

large amounts of tumor-reactive TGF- β -insensitive (GFP staining positive) CD8⁺ T cells and the presence of apoptosis in tumor tissues (Fig. 3A). Almost all of these infiltrated CD8⁺ T cells are GFP positive, suggesting that all these CD8⁺ T cells were adoptively transferred (Fig. 3E). Also, CD4⁺, B cells, and NK cells, thought not abundant, were found in the tumor tissue (Fig. 3B-D). Tumors in animals who received adoptive transfer of naïve CD8⁺ T cells and tumor-reactive control CD8⁺ T cells (Fig. 3A) showed little or no CD8⁺ T cells. In the latter two groups, CD8⁺ T cells are present only in the stromal tissues of the lung. Although CD8⁺ T cells were not observed in tumors of animals who received tumor-reactive control CD8⁺ T cells, some lymphocytic infiltration was evident histologically. However, such lymphocytic infiltration was more

prominent in tumors of the group who received tumor-reactive TGF- β -insensitive CD8⁺ T cells. Very little CD4⁺ T cells, B cells, and NK cells were observed in the tumor tissue of the tumor-reactive control CD8⁺ T cells treatment group. No lymphocytic infiltration was

noted in tumors of animals who received naïve CD8⁺ T cells (Fig. 3A,B,D), except some B cells (Fig. 3C). The degree of infiltration of different kinds of lymphocytes were evaluated by standard fluorescent index, which corresponds to the fluorescent intensity criterion (positive lymphocytes/100 tumor cells/1,000 μm^2 : - : <5; \pm : 6-10; +: 11-30; ++: 31-50; +++: 51-70; ++++: >70) (Fig. 3G). In general, much higher TGF- β expression was detected in the tumor parenchyma than peripheral non-tumor tissue in all three groups (Fig. 3F).

Secretion of Cytokines in Tumor Tissue

A very high level of perforin (Fig. 4A), along with an abundance of infiltrated tumor-reactive TGF- β -insensitive (GFP staining positive) CD8⁺ T cells was expressed in tumor tissue. The superimposed image suggests that the overwhelming majority of perforin originated from tumor-reactive TGF- β -insensitive CD8⁺ T cells. A marginally high level of IFN- γ (Fig. 4B) and IL-2 (Fig. 4D) and a moderately high level of nitric oxide (Fig. 4C) were expressed in tumor tissue. IFN- γ , IL-2, and nitric oxide appeared to have originated primarily from tumor-reactive TGF- β -insensitive CD8⁺ T cells. Low levels of TNF- α expression were demonstrated in tumor tissue. The majority of TNF- α expression appeared to have originated from tumor-reactive TGF- β -insensitive CD8⁺ T cells (Fig. 4E). Increased levels of IFN- γ and IL-2 in tissue corresponded to serum levels (data now shown). Perforin was not expressed in naïve CD8⁺ T cells and was expressed very minimally in tumor-reactive control CD8⁺ T cells (Fig. 4A). The contribution of IFN- γ , IL-2, nitric oxide, and TNF- α expression from naïve CD8⁺ T cells and tumor-reactive control CD8⁺ T cells appears to be negligible (Fig. 4B). A summary of cytokine expression was described as




Fig. 2. Histological finding of the tumor. Representative histology (H&E staining) of metastatic tumor nodules in the lungs from animals received adoptive transfer of naïve CD8⁺ T cells (A and B), GFP-infected CD8⁺ T cells (C and D), and TβRIIDN-infected CD8⁺ T cells (E and F), in mice 40 days following adoptive transfer of CD8⁺ T cells into recipients at 21 days following injection of tumor cells. In the lung of a mouse that received transfer of naïve CD8⁺ T cells, a portion of a large tumor (A, 3 mm in diameter) showing marked cytological polymorphism is illustrated. In the lung of a mouse transferred with GFP-infected CD8⁺ T cells, there is one smaller tumor nodule (C, 1.5 mm in diameter), which demonstrates some degree of lymphocytic infiltration and degenerative changes of tumor cells. In the lung of a mouse that received TβRIIDN-infected CD8⁺ T cells, there is a smaller tumor nodule (E, 0.5 mm in diameter). Within this tumor, heavy lymphocytic infiltrates and marked degenerative changes of tumor cells can be seen (F). Immunohistological staining for the expression of PCNA in tumor cells: naïve (G, H), GFP (I, J), TβRIIDN (K, L). The brown cells are PCNA-positive cells. All specimens were observed at 100-fold, 200-fold, or 400-fold magnification.




Fig. 3.

standard fluorescent index (positive signal/100 tumor cells/1,000 μm^2 : -: <5; \pm : 6–10; +: 11–30; ++: 31–50; +++: 51–70; ++++: >70) (Fig. 4F)

Apoptosis of Tumor Cells by the Treatment of Tumor-Reactive TGF- β -Insensitive CD8⁺ T Cells

A prominent feature of TUNEL assay in the tumor tissue in this study is the infiltration of CD8⁺ T cells into the tumor parenchyma and the presence of apoptosis in tumor cells of animals who received adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells (the T β RIIDN group) (Fig. 5). Tumors in the animals of the other two groups showed little or no infiltration of CD8⁺ T cells and demonstrated no evidence of apoptosis. However, CD8⁺ T cells are present in the stromal tissue of the lung in animals of all groups. Meanwhile, there are large amounts of CD8⁺ T cells that were induced to undergo apoptosis outside the margin of the tumor sites in animals treated with adoptive transfer of naïve CD8⁺ T cells and tumor-reactive control CD8⁺ T cells.

DISCUSSION

A significant part of modern tumor immunology has focused on the identification of tumor-specific antigens and the cytolytic T-cells specific for these peptides [25]. When such antigens are defined, therapeutic approaches use the antigen as the target [26]. However, any immunotherapeutic approach for cancer necessitates cytotoxic T lymphocytes to enter the tumor parenchyma. In the past, despite the ability to generate immune cells that are reactive against tumor antigens, evasion of the host immune surveillance by tumor cells persisted leading to eventual tumor progression [14,27,28]. Many possible mechanisms of a tumor's ability to evade host immune surveillance have been elucidated. These include the down-regulation of tumor antigen processing, the inhibitory role of CD4⁺CD25⁺ T regulatory cells, and the role of tumor-derived immunosuppressive cytokines, which include VEGF, IL-10, and TGF- β [28–32]. High levels of TGF- β produced by tumor cells are able to deter immune cells from entering the tumor parenchyma [33–38]. Results of the present study seem to indicate that TGF- β was a

very important immunosuppressant, as TGF- β insensitive CD8⁺ T cells were able to infiltrate into the tumor parenchyma and to induce apoptosis in tumor cells, and its immunosuppressive role in cancer progression has been well established.

The mouse prostate cancer, TRAMP-C2, represents an aggressive line of malignant cells, which secrete large amounts of TGF- β . Presently, we have demonstrated that TRAMP-C2 tumors, due to their secretion of large amounts of TGF- β [24], possess potent immunosuppressive power resulting in the inability of conventional CD8⁺ T cells to effectively infiltrate into the tumor tissue, resulting in a failure of these recipient animals to reject tumors. In this study, it is apparent that TGF- β -mediated evasion of the host immune surveillance system plays a critical role. Once these tumor-reactive CD8⁺ T cells were rendered insensitive to TGF- β , they possessed the ability to eradicate established pulmonary metastases in a mouse prostate cancer model and to prolong survival in tumor-bearing mice. We observed that adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells can overcome the tumor-derived immune suppressive mechanisms. The most prominent characteristic of these tumor-reactive TGF- β -insensitive CD8⁺ T cells is their ability to escape the immunosuppressive effect of tumor-derived TGF- β to specifically infiltrate into the tumor parenchyma, and to function as potent effectors against tumor cells that induce apoptosis in these established TRAMP-C2 tumors. Our experience has indicated that a mere acquisition of reactivity against tumor cells in CD8⁺ T cells was insufficient to achieve tumor infiltration by these cells [39,40]. Therefore, in order for tumor infiltration to occur, these CD8⁺ T cells must be rendered tumor-reactive as well as TGF- β -insensitive. Clinically, the large number of circulating tumor antigen-specific CD8⁺ cytotoxic T lymphocytes in individuals with cancer does not correlate with T-cell infiltration into cancer tissues or tumor regression [41,42]. The inability of immune cells, especially cytotoxic CD8⁺ T cell, to infiltrate into the tumor parenchyma is perhaps, the most important event in determining evasion from host immune surveillance by tumor cells. This is because all tumor cells have acquired the ability to inhibit the host immune system.

Fig. 3. Infiltration of lymphocytes into the tumor parenchyma. **A:** In contrast to GFP-infected and naïve CD8⁺ T cells, only T β RIIDN-infected CD8⁺ T cells can effectively infiltrate into the tumor parenchyma. Furthermore, unlike animals who were treated with T β RIIDN-infected CD8⁺ T cells, CD4⁺ T cells (**B**), and NCAM cells (**D**) except BLCAM cells (**C**) in animals treated with GFP-infected and naïve CD8⁺ T cells lacked the ability to effectively infiltrate into the tumor parenchyma. The source of CD8⁺ T cells within the tumor was confirmed to originate from T β RIIDN-infected CD8⁺ T cells that were adoptively transferred, as evidenced by nuclear-CD8⁺-GFP protein triple staining (**E**). When quantifying the relative contributions of the various immune cells and their ability to infiltrate into the tumor parenchyma, tumor-reactive TGF- β -insensitive CD8⁺ T cells contributed significantly, when compared to CD4⁺ T cells, BLCAM cells, and NCAM cells (**G**). In general, much higher TGF- β expression was detected in the tumor parenchyma than peripheral non-tumor tissue in all the three groups (**F**).




Fig. 4.




Fig. 5. Apoptosis of tumor cells. Immunofluorescent staining for nuclei, CD8⁺ T cells, and apoptosis. Representative tissue sections showing pulmonary metastasis were simultaneously stained for cell nucleus (blue), CD8⁺ T cells (red), and apoptosis (green). The tumor site was identified by the nuclear staining (blue). CD8⁺ T cells were identified mainly in the lung tissues not in the tumor with the exception of the T β RIIDN group, in which CD8⁺ T cells (red) were also found within the tumor parenchyma. Frequent tumor apoptotic sites (green) were only found in the T β RIIDN group. Although few CD8⁺ T cells were found undergoing apoptosis (yellow), the majority of the apoptotic cells were derived from the tumor cells (green). (magnification: $\times 400$) Apoptotic activity was evident within the tumor parenchyma of the T β RIIDN group. In contrast, tumors in animals who received treatments with GFP infected and naïve CD8⁺ T cells did not exhibit tumor cells apoptosis within the tumor parenchyma. Large amounts of CD8⁺ T cells exhibited apoptotic activity along the periphery of the tumor parenchyma.

Immunologists have studied properties of tumor cells and have recognized many factors that tumor cells have employed to inhibit the host immune system. These factors include soluble MHC class I chain-related (MIC)

molecules [43–45], cytotoxic T lymphocyte antigen-4 (CTLA-4) [46], interleukin-13, CD4⁺CD25⁺ regulatory T cells, and CD4⁺ natural killer T cells [47]. TGF- β has been recognized as one such tumor-derived immune

Fig. 4. Secretion of cytokines in tumors of different groups. **A:** A very high level of perforin is expressed in tumor tissue and corresponds to tumor-reactive TGF- β -insensitive CD8⁺ T cells that have effectively infiltrated into the tumor parenchyma. The merged image suggests that the overwhelming majority of perforin originated from tumor-reactive TGF- β -insensitive CD8⁺ T cells. Perforin was not expressed in naïve CD8⁺ T cells and expressed very minimally in GFP-infected CD8⁺ T cells. A marginally high level of IFN- γ (**B**), IL-2 (**D**), and a moderately high level of nitric oxide (**C**) corresponding to tumor-reactive TGF- β -insensitive CD8⁺ T cells is expressed in the tumor tissue. IFN- γ , IL-2, and nitric oxide appear to have originated primarily from tumor-reactive TGF- β -insensitive CD8⁺ T cells. The contribution of naïve and GFP-infected cells to IFN- γ , IL-2, and nitric oxide expression appears to be negligible. **E:** Low levels of TNF- α expression corresponding to tumor-reactive TGF- β -insensitive CD8⁺ T cells are demonstrated in the tumor tissue. The majority of TNF- α expression appears to have originated from tumor-reactive TGF- β -insensitive CD8⁺ T cells. The contribution of naïve and GFP-infected CD8⁺ T cells to TNF- α expression appears to be negligible. **F:** The relative contributions of the various cytokines were stratified according to different cell types.

suppressor [17]. Results of the present study suggest that TGF- β is a very important tumor-derived immune suppressor. In addition to their ability to infiltrate into the tumor parenchyma, tumor-reactive TGF- β -insensitive CD8⁺ T cells are readily activated [48], conferring them robust anti-tumor effector function, as indicated by the production of relevant cytokines and widespread apoptosis in tumor cells.

Once the TGF- β -insensitive cytotoxic T lymphocytes are allowed to infiltrate into the tumor parenchyma, these effector cells are able to launch powerful anti-tumor activities. Results of the present study indicated that large amounts of cytokines, including perforin, nitric oxide, IFN- γ , IL-2, TNF- α , were detected in tumor tissue. The infiltrated tumor-reactive TGF- β -insensitive CD8⁺ T cells produce these relevant cytokines, which mediate the tumor-killing activities. Lysis of tumor cells can be mediated by perforin, IFN- γ , IL-2, and nitric oxide [49]. The increased levels of IL-2 will also prolong persistence of transferred CD8⁺ T cells [4]. Therefore, tumors challenged with tumor reactive TGF- β -insensitive CD8⁺ T cells will be induced to undergo apoptosis. In contrast, tumors in those animals who received adoptive transfer of naïve CD8⁺ T cells or tumor-reactive control CD8⁺ T cells, survived as these CD8⁺ T cells were unable to infiltrate into the tumor parenchyma and were not allowed to interact with tumor cells. Without this "shield effect" of TGF- β , we observed a large amount of CD8⁺ T cells that were induced to undergo apoptosis outside the margin of the tumor sites in these latter groups of animals. While we have observed infiltration of tumor-reactive TGF- β -insensitive CD8⁺ T cells into the tumor parenchyma, we have also observed the occasional presence of other immune cells (CD4⁺, NK, B cells). In other treatment groups (those who received adoptive transfer of naïve CD8⁺ T cells or tumor-reactive control CD8⁺ T cells), these non-CD8⁺ T immune cells were not observed in the tumor parenchyma. It is unclear whether these non-CD8⁺ T cells infiltrated into the tumor parenchyma by a yet unknown mechanism or diffused into the tumor tissue alone with the tumor-reactive TGF- β -insensitive CD8⁺ T cells. Nevertheless, the presence of other immune cells in the tumor parenchyma suggests a possible interaction between tumor-reactive TGF- β -insensitive CD8⁺ T cells with other types of immune cells and warrants further investigation in the future.

In summary, adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells resulted in infiltration of these immune cells into the tumor parenchyma, secretion of relevant cytokines, and induction of apoptosis in tumor cells. These results support the concept that TGF- β is an important target in cancer immunotherapy.

ACKNOWLEDGMENTS

This study was supported in part by grants from the Department of Defense (PC970410, PC001491, and PC030038) and the National Cancer Institute (CA107186).

REFERENCES

1. Ioachim HL. The stroma reaction of tumor: An expression of immune surveillance. *J Cell Biochem Suppl* 1979;57:465-475.
2. Economou JS, Economou JS, Beldegrun AS, Glaspy J, Toloza EM, Figlin R, Hobbs J, Meldon N, Kaboo R, Tso CL, Miller A, Lau R, McBride W, Moen RC. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. *J Clin Invest* 1996;97:515-521.
3. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Beldegrun AS. Multicenter, randomized, phase III trial of CD8⁺ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. *J Clin Oncol* 1999;17:2521-2529.
4. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8⁺ T cells clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. *Proc Natl Acad Sci USA* 2002;99:16168-16173.
5. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. *Proc Natl Acad Sci USA* 2004;101:14639-14645.
6. Miescher S, Whiteside TL, Moretta L, Von FV. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. *J Immunol* 1987;138:4004-4011.
7. Svennevig JL, Lunde OC, Holter J, Bjorgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. *Br J Cancer* 1984;49:375-377.
8. Whiteside TL. Tumor infiltrating lymphocytes as antitumor effector cells. *Biotherapy* 1992;5:47-61.
9. Meischer S, Stoeck L, Qiao C, Barras L, Barrelet XX^{Q3}, von Flidner V. Proliferative and cytolytic potentials of purified tumor infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T cell receptor expression. *Int J Cancer* 1998;42:659-666.
10. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormality, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. *Clin Cancer Res* 2002;8:3133-3145.
11. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick P, Bell M, Edwards R, Whiteside TL. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. *Int J Cancer* 1996;68:276-284.
12. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. *Nat Rev Cancer* 2003;3:666-675.
13. Yee C, Greenberg P. Modulating T-cell immunity to tumours: New strategies for monitoring T-cell responses. *Nature Rev Cancer* 2002;2:409-419.
14. Wojtowicz PS. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy. *J Immunother* 1997;20:165-177.
15. Letterio JJ, Roberts AB. Regulation of immune responses by TGF- β . *Ann Rev Immunol* 1998;13:51-69.

16. Fortuvel NO, Hatzfeld A, Hatzfeld J. Transforming growth factor- β : Pleiotropic role in the regulation of hematopoiesis. *Blood* 2000;96:2022–2036.
17. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor- β signaling in T cells. *Nat Med* 2001;7:1118–1122.
18. Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ. Tumor-derived TGF- β reduces the efficacy of dendritic cell/tumor fusion vaccine. *J Immunol* 2003;170:3806–3811.
19. Won J, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. *Cancer Res* 1999;59:1273–1277.
20. de Visser KE, Kast MW. Effects of TGF- β on the immune system: Implications for cancer immunotherapy. *Leukemia* 1999;13:188–199.
21. Terabe M, Matsui SM, Park J, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA. Transforming growth factor- β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. *J Exp Med* 2003;198:1741–1752.
22. Shah AH, Tabayoyong WB, Kimm SY, Kim SJ, Van Parijs L, Lee C. Reconstitution of lethally irradiated mice with TGF- β insensitive bone marrow leads to myeloid expansion and inflammatory disease. *J Immunol* 2002;169:3485–3491.
23. Shah AH, Tabayoyong WB, Kundu SD, Kim SJ, Van Parijs L, Liu VC, Kwon E, Greenberg NM, Lee C. Suppression of tumor metastasis by blockade of TGF- β signaling in bone marrow cells through a retroviral mediated gene therapy in mice. *Cancer Res* 2002;62:7135–7138.
24. Zhang Q, Yang X, Pin M, Javonovic B, Kuzel T, Kim SJ, Van Parijs L, Greenberg NM, Liu VC, Guo YL, Lee C. Adoptive transfer of tumor-reactive TGF- β -insensitive CD8⁺ T cells: Eradication of autologous mouse prostate cancer. *Cancer Res* 2005;65:1761–1769.
25. van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. *Curr Opin Immunol* 1997;9:684–693.
26. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD. DNA-based immunization by in vivo transfection of dendritic cells. *Nat Med* 1996;2:1122–1128.
27. Rosenberg SA. Development of effective immunotherapy for the treatment of patients with cancer. *J Am Coll Surg* 2004;198:685–696.
28. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. *Nat Immunol* 2002;3:999–1005.
29. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR. Identification of human cancers deficient in antigen processing. *J Exp Med* 1993;177:265–272.
30. Li J, Hu P, Khawli LA, Epstein AL. Complete regression of experimental solid tumors by combination LEC/chTNF-3 immunotherapy and CD25⁺ T-cell depletion. *Cancer Res* 2003;63:8384–8392.
31. Kirkbride KC, Blobe GC. Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. *Expert Opin Biol Ther* 2003;3:251–261.
32. Torre AG, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. A highly immunogenic tumor transfected with a murine transforming growth factor type β 1 cDNA escapes immune surveillance. *Proc Natl Acad Sci USA* 1990;87:1486–1490.
33. Chen TC, Hinton DR, Yong VW, Hofman FM. TGF- β 2 and soluble p55 TNFR modulate VCAM-1 expression in glioma cells and brain derived endothelial cells. *J Neuroimmunol* 1997;73:155–161.
34. Xu J, Menezes J, Prasad U, Ahmad A. Elevated serum transforming growth factor beta1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM. *J Virol* 2000;74:2443–2446.
35. Abou SM, Baer HU, Friess H, Berberat P, Zimmermann A, Graber H, Gold L, Korc M, Buchler MW. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. *Am J Surg* 1999;177:209–215.
36. Wikstrom P, Bergh A, Damber JE. Transforming growth factor-beta1 and prostate cancer. *Scand J Urol Nephrol* 2000;34:85–94.
37. Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: A possible tumor marker. *Lung Cancer* 1996;16:47–59.
38. Tang B, Bottinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, Letterio JJ, Wakefield LM. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. *Nat Med* 1998;4:802–807.
39. Boon T, Van D, Bruggen P. Human tumor antigens recognized by T lymphocytes. *J Exp Med* 1996;183:725–729.
40. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. *Immunity* 1999;10:281–287.
41. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science* 2002;298:850–854.
42. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. *J Intern Med* 2001;250:462–475.
43. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. *Nature* 2002;419:734–738.
44. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. *Nat Rev Immunol* 2001;1:209–219.
45. Pardoll DM. Spinning molecular immunology into successful immunotherapy. *Nat Rev Immunol* 2002;2:227–238.
46. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. *Annu Rev Immunol* 2001;19:565–594.
47. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. *Nat Immunol* 2000;1:515–520.
48. Bommireddy R, Saxena V, Ormsby I, Yin M, Boivin GP, Babcock GF, Singh RR, Doetschman T. TGF- β 1 regulates lymphocyte homeostasis by preventing activation and subsequent apoptosis of peripheral lymphocytes. *J Immunol* 2003;170:4612–4622.
49. Joseph N, Blattman E, Greenberg PD. Cancer Immunotherapy: A treatment for the masses tumor. *Science* 2004;305:200–205.